The agreement includes the option for the U.S. to buy additional doses in the second quarter, the companies say.

Wall Street looks set to recoup all -- and more -- of last week's Omicron-linked declines as investors look past risks tied to the new variant, which may be milder and less virulent that first anticipated.

GlaxoSmithKline and its U.S. partner, Vir Biotechnology, said Tuesday that their COVID antibody is effective against all mutations of the new Omicron variant.

Stocks futures extend gains as Omicron risks fade, Glaxo and Vir Bio say COVID therapy effective against variant; Intel plans potential $50 billion Mobileye IPO; Samsung merges phone and electronics division in major restructuring and Elon Musk says Biden's EV incentives shouldn't pass congress.

Jim Cramer says market sentiment may be fickle, but it also can be a powerful driver of buying opportunities for investors who do their homework.

Tesla CEO Musk discusses succession plans and Twitter with shareholders.

The company has made clear what it plans on the Las Vegas Strip, but it has a fast-approaching deadline.

Long-delayed futuristic looking electric vehicle will be in production by the middle of 2023